Immunology CRO Services

Comprehensive evaluation of therapeutic candidates, including immune profiling, safety and efficacy testing, dose optimization, and mechanistic insights with InnoSer’s immunology CRO services

Forschungskompetenzen anzeigen

Contact Our Immunology Experts

Home » Immunology CRO services

Preclinical Immunology Research with InnoSer

✓ Molecular and Immunology Techniques

✓ Intelligente pathologische Beurteilungen

✓ Pharmacology Expertise

✓ Validated Models

✓ Maßgeschneiderte Studiendesigns

✓ Speziell dafür zuständige Forschungskoordinatoren

Vereinbaren Sie einen Beratungstermin mit unserem Team

As a European preclinical immunology contract research organization (CRO), InnoSer provides you with an integrated immunology portfolio spanning from in vitro to in vivo research services. InnoSer works with well-published in vitro and in vivo models relevant for multiple indications ranging from hypersensitivity, inflammatory, to autoimmune diseases. By choosing InnoSer as your partner CRO, you will work alongside our expert study directors who take a collaborative approach for your study, accommodating your study timelines and budget needs.

InnoSer’s immunology expert team possesses relevant experience in working with multiple therapy types ranging from novel delivery methods, vaccines, small molecules, biologics to cell and gene therapy approaches. Complemented by our pharmacology expertise (such as target validation, biomarker identification, and validation, as well as PK/PD profiling), the InnoSer team works with you to confidently demonstrate the safety and efficacy profile of your novel investigational compound.

Möchten Sie mehr über unsere präklinischen Dienstleistungen erfahren?

Entdecken Sie unsere am häufigsten gestellten Fragen (FAQs)

Preclinical Immunology Disease Model Catalogue

In Vitro Immuno-assays

Perform initial screening tests using InnoSer’s in vitro immunoassays to select your lead candidate compounds and progress to in vivo studies with confidence

DTH-Mausmodell

Evaluate your compound’s immunomodulatory or immunosuppressive potential in the delayed-type hypersensitivity (DTH) mouse model

mRNA/RNA Therapies

Vaccine Testing and mRNA/RNA therapies: LNP delivery, in vitro assays, biodistribution, PKPD, immunogenicity, dose optimization and more

IBD-Mausmodelle

Test the efficacy of your novel compounds to improve gut health in individuals with IBD through InnoSer’s preclinical expertise and portfolio of IBD mouse models

Diabetes Mouse Model

Testen Sie die Wirkung Ihrer neuartigen, in der Erprobung befindlichen Therapie auf die Blutzuckerkontrolle und die Glukosetoleranz dank InnoSers Fachwissen im Bereich Typ-1-Diabetes dDiabetes mMaus mModells

EAE-Mausmodell

Investigate your compound’s efficacy on the inflammation and immune component of Multiple Sclerosis using the EAE mouse model

IL-23-induziertes Psoriasis-Mausmodell

Perform quick efficacy tests to evaluate your novel psoriasis treatment strategies using the acute IL-23-Induced Psoriasis Mouse model

Ist Ihr Modell nicht dabei? Wir helfen Ihnen gerne weiter!

Unsere Experten sind auf maßgeschneiderte Lösungen spezialisiert, die genau auf Ihre individuellen Forschungsanforderungen zugeschnitten sind. Lassen Sie uns gemeinsam besprechen, wie wir Ihr Projekt unterstützen können.

Kontaktieren Sie uns für eine maßgeschneiderte Lösung

Immunology Research with InnoSer

Darstellung des Tumorwachstums mittels BLI für Studien zur Arzneimittelentwicklung

Validated research models

As a preclinical immunology CRO, InnoSer performs efficacy studies in well-established and clinically relevant research models. Standardized study protocols ensure consistency and reproducibility of your results. With flexible and fast study start times you can perform your immunology research at an accelerated pace. InnoSer’s expert team continuously works on validating new research models; if you don’t see your research model of choice on our webpage do not hesitate to contact us.

Histopathology stainings for reclinical cancer research studies testing toxicity of drugs in development

Complemented with molecular and immunology techniques

Carefully designed studies complemented with the most relevant readouts are required to confidently demonstrate your investigational compound’s efficacy. InnoSer offers a wide range of readouts to perform in vitro assays (immune cell activation, immunotoxicity, T-cell activation), cytokine and immune cell profiling (flow cytometry, MSD, ELISA), and biomarker quantification. Additionally, InnoSer works with in-house veterinary pathologists, providing you with accurate and rapid histopathology assessments.

in vivo oncology model being used for preclinical immuno-oncology research

Powered by complementary pharmacology expertise

InnoSer’s immunology CRO services are complemented with pharmacology studies that can be done before or alongside your efficacy studies. Fee-for-service pharmacology studies offered by InnoSer’s team include ADME/ DMPK studies, PK/PD profiling, biodistribution, and early-stage toxicology (dose-response, maximum tolerated dose [MTD], etc.,) studies.

Die Menschen hinter Ihrer Forschung

Céline Erens, PhD, Oncology & Immunology Principal Scientist

Ein Expertenteam unter der Leitung unserer Studienleiterin für Immunonkologie, Céline Erens, unterstützt Sie bei der Auswahl der richtigen Instrumente und der Ausarbeitung optimaler Studiendesigns. Die Begleitung der präklinischen Prüfung Ihrer Leitverbindungen auf der Grundlage fundierter Fachkenntnisse ist der Schlüssel zur Beschleunigung Ihrer Arzneimittelentwicklung.

Dr. Yanick Fanton, wissenschaftlicher Leiter

Als Chief Science Officer bei InnoSer ist Yanick für alle Kundenstudien bei InnoSer verantwortlich und kümmert sich um die wissenschaftliche und technische Koordination.

Häufig gestellte Fragen

What is a preclinical immunology CRO?

A preclinical immunology contract research organization (CRO) provides specialized research services to support the development and approval of novel immunomodulatory therapeutics. As a preclinical European immunology CRO, InnoSer regularly partners with leading biotechnology and pharmaceutical industry innovators to:

Offer expert advice and perform a wide range of drug development studies related to pharmacology, early-stage toxicology, and efficacy for various immunomodulatory compound testing.
Test the therapeutic profile of novel investigational compounds utilizing highly translational in vitro and in vivo models for autoimmune, inflammatory, and hypersensitivity diseases.
Develop and validate novel models (e.g., humanized mouse models for efficacy testing of various immunomodulatory compounds).
Partnering with a preclinical immunology CRO like InnoSer provides you with access to cutting-edge resources, accelerates your drug development process, and allows your team to focus on its core objectives without the need for a complex in-house setup.

Contact InnoSer to discuss how we can support your preclinical immunology research goals.

Why should I choose InnoSer as my partner CRO for preclinical immunology research?

At InnoSer, we provide expertise, flexibility, and tailored solutions to support your preclinical immunology research, helping you generate reliable, high-quality data while keeping you thoroughly informed throughout the process. By working with InnoSer, you can:

Assess the pharmacologic (e.g., PK/PD, tolerability, dose-response) and toxicologic profile (e.g., maximum tolerated dose) of your compound before moving to efficacy studies
Demonstrate the efficacy profile of your novel immunomodulatory compounds with our highly translationally relevant in vitro and in vivo models for a range of autoimmune, inflammatory, and hypersensitivity disorders
Assess immune cell profiling with advanced technologies: obtain valuable insights into modulating cytokine profiles, immune cell recruitment, and immune memory formation using flow cytometry and mesoscale discovery (MSD)
Track the biodistribution of your compounds in real-time: leverage InnoSer’s expertise in IVIS Imaging and monitor your drug distribution in vivo
Get expert guidance and real-time study updates: Stay informed with in-life study reports, mid-study data reviews, and a secure data-sharing platform.

Ready to Accelerate Your Immunology Research? Contact InnoSer today to discuss how our preclinical immunology CRO services can support your therapeutic development and help you achieve your research goals faster.

What immunology models should I choose for my research?

The choice of immunology models depends on the stage of your research, specific disease area, mechanism of action (MoA) of your compound, as well as objectives of your research. For example, if you have multiple lead compounds and you would like to select only a few to progress to efficacy studies, in vitro assays may be a suitable choice due to the lower price and time investment needed.

To support lead optimization, complementary studies such as pharmacokinetics (PK), pharmacodynamics (PD), tolerability, and dose-response assessments can provide critical data before advancing to efficacy testing. These studies help optimize dosing regimens, refine formulations, and prioritize compounds with the most favorable PK/PD profiles.

When moving into in vivo efficacy studies, disease-specific models are essential for assessing your compound’s therapeutic potential. For example, InnoSer’s EAE mouse models are widely used for multiple sclerosis research, while IBD mouse models help evaluate test compounds for Crohn’s disease and ulcerative colitis. Psoriasis models (such as IL-23-induced skin inflammation) allow for the efficacy of compounds on ameliorating skin inflammation, and DTH mouse models are useful for assessing T-cell mediated immune responses.

At InnoSer, our expert team works closely with you to identify the most suitable models and plan an efficient study strategy, ensuring your research progresses smoothly without any costly delays. Contact us today to discuss your research needs!

I don't see my model of choice in your mouse model list, does InnoSer have capabilities to validate new immunology disease models on request?

Yes! At InnoSer, we offer flexible and customizable preclinical immunology CRO solutions, including the development and validation of new immunology research models to meet your specific research needs. If your model of interest is not listed on our website, reach out to our team, who will work together with you to develop and validate novel in vivo and/or in vitro models, ensuring reproducibility and reliability for your preclinical research.

Speak with our immunology experts to discuss your specific study goals.

Entdecken Sie die richtigen Werkzeuge für Ihre Forschung.

Explore and compare our immunology models to identify the perfect model for your study needs.

Finden Sie den passenden Forschungsansatz

Broschüre zur Onkologie zum Herunterladen

Bleiben Sie neugierig: Weitere Artikel zum Entdecken

Einblick in die wichtigsten In-vitro-Dienstleistungen von InnoSer im Bereich der Onkologie: PD-1/PD-L1-Blockade-Assay

22. Oktober 2024

Immun-Checkpoint-Blockade in der onkologischen Wirkstoffforschung In den letzten Jahren hat sich die Immun-Checkpoint-Blockade als bahnbrechende therapeutische Strategie in der Immunonkologie etabliert. Der Programmierte-Zelltod-1-Rezeptor (PD-1) und sein Ligand, der Programmierte-Zelltod-Ligand 1 (PD-L1)...

AAALAC-Akkreditierung

InnoSer hat die AAALAC-Akkreditierung erhalten und damit sein Engagement für einen verantwortungsvollen Umgang mit Tieren unter Beweis gestellt. AAALAC International ist eine gemeinnützige Organisation, die sich durch freiwillige Akkreditierungs- und Bewertungsprogramme für den artgerechten Umgang mit Tieren in der Wissenschaft einsetzt. Die Einrichtungen von InnoSer in den Niederlanden und Belgien sind seit 2016 bzw. 2020 AAALAC-akkreditiert. Weitere Informationen zum AAALAC-Akkreditierungsprogramm finden Sie hier.

AAALAC-Logo

Tierschutz

Die 3Rs wirken sich auf alle Bereiche aus, von politischen und regulatorischen Veränderungen bis hin zur Entwicklung und Einführung neuer Technologien und Ansätze. Aus diesem Grund engagiert sich InnoSer kontinuierlich für diese Prozesse und überwacht sie. Die von uns umgesetzten Maßnahmen maximieren unsere Fähigkeit, den Einsatz von Tieren zu ersetzen, zu reduzieren und zu verfeinern, und unterstützen unser Bekenntnis zu diesen Grundsätzen in der Forschung und der Arzneimittelentwicklung.

Unser Engagement für die 3Rs

Unverbindlich – Los geht’s

Kontakt

info@innoserlaboratories.com